Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma.
The concentration of cysteine protease inhibitor cystatin C was determined in sera from 59 patients with non-Hodgkin B-cell lymphoma using ELISA. The sera from 43 age and sex matched healthy blood donors served as controls. Cystatin C was significantly increased in sera of patients without therapy (mean 1136+/-SE 105.7ng/ml, p=0.00001) and with therapy (mean 1073+/-52ng/ml, p=0.001) compared to controls (mean 819+/-28ng/ml). The highest levels were determined in sera of patients with a relapse (mean 1680+/-196ng/ml). By using immunofluorescence staining and confocal microscopy we determined immature dendritic cells as a major population of cystatin C positive cells in affected lymph nodes. Our study reports for the first time that cystatin C is a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma.
Mulaomerović
Adaleta
A
Medical Faculty, University of Tuzla, Bosnia and Herzegovina.
Halilbasić
Alma
A
Cickusić
Elmir
E
Zavasnik-Bergant
Tina
T
Begić
Lejla
L
Kos
Janko
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D003404:Creatinine / Q000097:blood; D055316:Cystatin C; D015891:Cystatins / Q000097:blood*; D003713:Dendritic Cells / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005455:Fluorescent Antibody Technique; D049670:History, 17th Century; D006801:Humans; D007167:Immunotherapy; D008198:Lymph Nodes / Q000378:metabolism / Q000473:pathology; D016393:Lymphoma, B-Cell / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D008297:Male; D018613:Microscopy, Confocal; D009364:Neoplasm Recurrence, Local / Q000378:metabolism*; D011379:Prognosis
D014408:Biomarkers, Tumor; C525030:CST3 protein, human; D055316:Cystatin C; D015891:Cystatins; D003404:Creatinine